GSK Malaysia

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) recently announced the launch of its Herpes Zoster vaccine (Shingles vaccine), Shingrix (MAL24056002ARZ), also known as Recombinant Zoster Vaccine, Adjuvanted (RZV) in Malaysia.

As Malaysia’s population trends towards an ageing demographic, the critical role of adult immunization is increasingly evident. Ensuring that adults receive essential vaccinations helps them remain active contributors to society and the economy. This contributes to prolonged productivity, sustained economic engagement, and reduced healthcare expenditures as they age.